The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valent, P.
Right arrow Articles by Lechner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valent, P.
Right arrow Articles by Lechner, K.

The Journal of Immunology, Vol 145, Issue 10 3432-3437, Copyright © 1990 by American Association of Immunologists

ARTICLES

Failure to detect IL-3-binding sites on human mast cells

P Valent, J Besemer, C Sillaber, JH Butterfield, R Eher, O Majdic, K Kishi, W Klepetko, F Eckersberger and K Lechner
I. Medical Department, University of Vienna, Austria.

IL-3, a pleiotropic lymphokine, has been termed mast cell growth factor because it promotes growth and differentiation of murine mast cells. Murine mast cells, in turn, express cell surface receptors for IL-3. Human rIL-3 has been shown to induce proliferation and differentiation of human basophils and to activate basophils via high affinity binding sites. To investigate whether human mast cells express IL-3R, binding studies with 125I-radiolabeled human rIL-3 were performed on HMC-1, a novel human mast cell line, and on pure populations (i.e., 93 to 99% purity) of human tissue mast cells obtained with mAb and C from dispersed lung (n = 2). Unexpectedly, neither enriched human lung mast cells nor HMC-1 cells bound radiolabeled human rIL-3 specifically. Moreover, human rIL-3 failed to promote uptake of [3H]thymidine, synthesis of histamine, histamine releasability, or changes in expression of mast cell differentiation Ag (YB5B8, CD54/ICAM-1, CD9/p24, CD33/gp67) on either human lung mast cells or HMC-1 cells. It is hypothesized that the fundamental difference in the biologic response to IL-3 between human and murine mast cells is due to a loss during evolution of mast cell high affinity IL-3 binding sites.


This article has been cited by other articles:


Home page
 BloodHome page
H.-J. Buhring, P. J. Simmons, M. Pudney, R. Muller, D. Jarrossay, A. van Agthoven, M. Willheim, W. Brugger, P. Valent, and L. Kanz
The Monoclonal Antibody 97A6 Defines a Novel Surface Antigen Expressed on Human Basophils and Their Multipotent and Unipotent Progenitors
Blood, October 1, 1999; 94(7): 2343 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
H. Ochi, W. M. Hirani, Q. Yuan, D. S. Friend, K. F. Austen, and J. A. Boyce
T Helper Cell Type 2 Cytokine–mediated Comitogenic Responses and CCR3 Expression During Differentiation of Human Mast Cells In Vitro
J. Exp. Med., July 19, 1999; 190(2): 267 - 280.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S C Bischoff, A Lorentz, S Schwengberg, G Weier, R Raab, and M P Manns
Mast cells are an important cellular source of tumour necrosis factor alpha  in human intestinal tissue
Gut, May 1, 1999; 44(5): 643 - 652.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.